Thoroughbred Financial Services LLC Makes New $742,000 Investment in argenx SE (NASDAQ:ARGX)

Thoroughbred Financial Services LLC acquired a new position in argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,208 shares of the company's stock, valued at approximately $742,000.

Several other large investors have also made changes to their positions in ARGX. Whipplewood Advisors LLC acquired a new position in shares of argenx in the fourth quarter valued at $37,000. Global Retirement Partners LLC raised its stake in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after acquiring an additional 61 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of argenx by 78.6% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock worth $46,000 after acquiring an additional 33 shares during the period. Finally, Huntington National Bank boosted its position in shares of argenx by 1,133.3% during the 4th quarter. Huntington National Bank now owns 74 shares of the company's stock valued at $46,000 after acquiring an additional 68 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ARGX. JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 14th. Robert W. Baird increased their price objective on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Wedbush reaffirmed an "outperform" rating and set a $715.00 price objective on shares of argenx in a research note on Friday. Piper Sandler increased their price target on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. Finally, Guggenheim raised their price target on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a report on Monday, March 10th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $690.33.

Remove Ads

argenx Trading Up 6.4 %

Shares of argenx stock traded up $34.72 during trading on Friday, hitting $580.94. The stock had a trading volume of 536,659 shares, compared to its average volume of 306,116. The firm has a market cap of $35.30 billion, a price-to-earnings ratio of -660.16 and a beta of 0.60. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21. The business's 50-day moving average is $607.87 and its 200 day moving average is $603.90.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.